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ABSTRACT 
Cardiovascular disease (CVD) is the leading cause of death in both men and women.  Although 
rates of CVD have declined, the overall number of people who will develop CVD is substantial.  
Given current demographic trends and the future “silver tsunami”, the number of deaths due to 
CVD and incident CVD events will increase.  Circulating levels of cardiac troponin have been 
shown to predict subsequent cardiac events.  In addition, the predictive value of cardiac troponin 
I (cTnI) may extend beyond death and myocardial infarction.  Most of the data come from 
observational studies of community dwelling subjects with relatively short follow-up period.  It 
is important to systematically evaluate whether serum levels of cTnI predict CVD outcomes over 
the long term.  In this dissertation, we evaluated a policy implemented at the Veteran’s Affair 
(VA) Healthcare System in Pittsburgh.  This policy required that serum cTnI levels be drawn on 
all patients admitted to the hospital with pain between their ears and hips.  After excluding 
patients who had an acute myocardial infarction or who died in the hospital, we identified 2901 
patients with a serum cTnI level drawn in fiscal 2010.  Follow-up continued for 365 days after 
their initial admission.  Patients with elevated troponin I levels were more likely to die, odds 
ratio (OR)=2.31;95% confidence interval (CI), 1.52-3.52; to have a myocardial infarction, 
OR=5.46; 95% CI, 2.70-11.04; to develop heart failure OR=2.15;95% CI, 1.35-3.42; and left 
ventricular hypertrophy, OR=2.11; 95% CI, 1.18-3.77. The association with one year mortality 
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was consistent in patients with and without acute coronary syndrome.  We found no association 
with diabetes or hypertension.   Serum cTn1 predicted chronic kidney disease in models that did 
not adjusted for baseline renal function, OR=2.06; 95% CI, 1.54-2.75.  Given the public health 
importance of CVD, our results show the value in a single measure of troponin in predicting 
future CVD events over one year of follow-up..  Our results suggest that the Pittsburgh VA 
Health System should continue measuring troponin on these patients. Patients with elevated 
levels could be targeted for interventions aimed at preventing CVD events. 
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1.0  OVERARCHING HYPOTHESIS 
To determine if an initial cardiac troponin I level >0.04ng/mL is associated with acute 
myocardial infarction (MI), all-cause mortality, and certain chronic medical conditions including 
diabetes, chronic kidney disease, hypertension, heart failure, left ventricular hypertrophy, 
cardiomyopathy or heart failure readmissions in a consecutive sample of primarily older adult 
males admitted to the Veteran’s Pittsburgh Healthcare System in fiscal year 2010. 
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2.0  BACKGROUND AND RATIONALE 
The figure below is inserted so that there is an item in the sample List of Figures To improve the 
early identification of acute coronary syndrome at the Pittsburgh Veteran’s Affairs (VA) 
Healthcare System a process was implemented to obtain troponin I levels on all patients with any 
complaint of discomfort between their ears and their hips.  In addition, all indeterminate troponin 
I levels (0.10ng/mL-0.60ng/mL) are reviewed daily by a staff cardiologist to determine if the 
indeterminate troponin I level is consistent with a presentation of acute coronary syndrome, an 
integral component in the evaluation of acute coronary syndrome.  
Biomarkers have been shown to predict short-term and long-term adverse cardiac events 
in those presenting with symptomatic stable acute coronary syndrome (ACS) [1, 2].   However, 
the presence of circulating troponins levels may have significant predictive value in the absence 
of an acute MI, (Figure 1) [3].  Because of this, there has been a change in the interpretation of 
circulating levels of cardiac troponin to general markers of myocardial damage instead of solely 
as specific identifiers of MI [3-5]. 
The prognostic value of an initial level of cardiac troponin I (cTnI) >0.04ng/mL warrants 
further investigation to determine the existence of an association with acute coronary syndrome, 
all-cause mortality and heart failure readmissions.  Furthermore, the relationship between the 
initial cTnI I level of >0.04ng/mL and chronic disease states such as diabetes, hypertension, 
chronic kidney disease, heart failure, cardiomyopathy and left ventricular hypertrophy given 
traditional risk factors including smoking status, age and male gender has not been extensively 
studied.  
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Figure 1. Relation between Troponin Level and Possible Cause 
 
According to the American Heart Association’s Heart Disease and Stroke 2013 Statistical 
Update, an estimated 83.6 million adults in the United States have at least one form of 
cardiovascular disease (CVD). Total cardiovascular disease includes hypertension, and coronary 
heart disease (CHD) with CHD further categorized into myocardial infarction (MI), and angina, 
heart failure (HF) and stroke.  Among those with CVD, 42.2 million are estimated to be ≥ 60 
years of age [6].  
On average, over 2150 Americans die each day from CVD or approximately 1 death 
every 40 seconds [7, 8]. The total direct medical costs of CVD are projected to increase from 
$272.5 billion in 2010 to $818 billion by 2030. The indirect costs from lost productivity 
secondary to morbidity and premature mortality associated with CVD are expected to increase 
by 61% or from $171.7 billion to $275.8 billion over the same time period [9]. 
CVD ranked the highest among all disease categories for inpatient hospital discharges, 
accounting for the first listed diagnosis in 5,802,000 cases in 2010 [6] (NHDS, NHBLI 
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tabulation). The distribution of aggregate hospital costs in 2011 was highest among diseases of 
the circulatory system at 18%. Specifically, the cost-per-stay for atherosclerosis increased from 
1997 to 2011, however, the aggregate costs decreased by 3% annually [10].  
The magnitude of this issue is further described by considering the impact of CHD in the 
United States. It is projected by 2030 the prevalence of CHD will increase by almost 17%. This 
is equivalent to an additional 8 million people with CHD when compared to the CHD prevalence 
rates from 2010 [9]. 
Improvement in treatment modalities (~47%) and risk factor management (~44%) are 
attributed to the decrease in age-adjusted mortality rates for CHD since the 1960’s [11, 12]. The 
age-adjusted prevalence of CHD in the United States from 2006 to 2010 declined from 6.7% to 
6.0%. In 2010, the prevalence of CHD was highest among people ≥ 65 years of age (19.8%), 
followed by those 45-64 years of age (7.1%) and then those 18-44 years of age (1.2%) [13].   
A dramatic change in the United States demographics will have a substantial impact on 
the nation’s public health system secondary to an aging society. The number of U.S. adults 65 
years or older will increase more than 50% by the year 2030 reaching approximately 71 million 
[13].  
Over the past century there has been a substantial shift in the leading cause of death for 
all age groups from acute illnesses and infectious diseases to chronic diseases. Heart disease 
poses the greatest risk accounting for 27.7% of deaths among U.S. adults aged 65 or older. 
Multiple chronic diseases are present in 66% of older Americans and treatment for this 
population accounts for two thirds of the country’s healthcare budget [14].  
Cardiovascular risk factors are frequently under-diagnosed and under-treated in older 
adults possibly secondary to the ambiguity that surrounds the usefulness of risk factor reduction 
in this population  [15, 16]. 
Although advances have been made, CHD remains a significant contributor to morbidity 
and mortality in the United States. One of the objectives of Healthy People 2020 is to lower the 
CHD death rate by 20%, from a baseline in 2007 of 126.0 per 100,000 (age adjusted to the year 
2000 standard population) to 100.8 per 100,000 by 2020 [17].   
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ACS is a major cause of emergency medical care and hospitalizations. The National 
Center for Health Statistics reported in 2004 that there were 1,565,000 hospitalizations for the 
primary or secondary diagnosis of acute coronary syndrome, 669,000 for unstable angina and 
896,000 for MI [18, 19].  
ACS describes clinical symptoms consistent with acute myocardial ischemia. ACS is 
classified based on the presence or absence of ST-segment elevation and includes non-ST-
segment elevation MI (NSTEMI), ST-segment elevation MI (STEMI) and unstable angina 
(USA). These high-risk features of coronary atherosclerosis are central to the use of emergency 
medical care services and hospitalization in the United States [20] . 
Diseases of the heart are ranked as the leading cause of death in 2010 according to the 
National Vital Statistic Reports [21]. Annually, an estimated 715,000 Americans will experience 
a heart attack, of these approximately 525,000 people will have a new heart attack and about 
190,000 people will suffer a recurrent event [6]. 
In the United States, cardiac related inpatient procedures have increased by 28% from 
5,939,000 in 2000 to 7,588,000 in 2010 [6]. This includes but is not limited to an estimated one 
million cardiac catheterizations, 954,000 percutaneous interventions (cardiac stents and/or 
balloon angioplasties) and 395,000 coronary artery bypass surgeries in 2010 [22]. 
The Global Registry for Acute Coronary Events (GRACE) is a multinational 
observational cohort study of ACS that had identified changes in practice relating to the use of 
pharmacological and interventional modalities for both NSTEMIand STEMI patients. This 
change in practice led to decreased rates of in-hospital death, cardiogenic shock and new MI 
among patients with NSTEMI and among patients with STEMI there has been a significant 
decrease in rates of death, cardiogenic shock, and HF[23]. Although GRACE showed 
advancements in ACS outcomes, there remains room for improvement. 
A National Quality Improvement Initiative entitled, “CRUSADE (Can Rapid Risk 
Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early 
Implementation of the ACC/AHA Guidelines)” enrolled 64775 patients who presented with 
chest pain and positive electrocardiographic changes (ECG) or cardiac biomarkers consistent 
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with NSTEMI. It was determined that 26% of the opportunities to provide the American College 
of Cardiology / American Heart Association’s (ACC/AHA) Guideline-centered care for patients 
with ACS, were missed [24].  
When patients present to the hospital with a suspected acute coronary syndrome a rapid 
diagnosis is essential. Patients are triaged quickly based on clinical symptoms, electrocardiogram 
(ECG) findings and myocardial biomarkers such as the troponin level. Decisions that are made 
on the basis of the initial evaluation have significant clinical and economic impact [25].  
2.1 CARDIAC TROPONIN 
Cardiac biomarkers are an essential component used to diagnose acute MI [26]. Considerable 
advances in the early detection of acute MI have been made over the past few decades secondary 
to the development of cardiac specific biomarkers [27, 28].  
After a MI there is a distinct release kinetic pattern that occurs. Initially, troponin is 
released from a loosely bound protein pool that is followed by a prolonged elevation in levels 
secondary to degradation of the contractile apparatus, (Figure 2) [3, 29, 30]. There is data 
indicating that the initial troponin pool may give information on the degree of micro-vascular 
reperfusion, while the size of the MI is reflected in the troponin level 3 or 4 days after the event 
[31]. 
Cardiac troponin consists of three subunits of tissue specific isoforms called troponin I, T 
and C, that are encoded by different genes. Troponin and tropomyosin are located on the actin 
filament in myofibrils and are necessary for calcium-mediated contraction of cardiac and skeletal 
muscle, (Figure 3) [32-35]. Troponin C does not have cardiac specificity as it is shared with 
skeletal muscle thus, it is not used as a diagnostic tool for the diagnosis of ACS [12, 36]. 
Troponin I, and troponin T, do possess cardiac specificity and sensitivity making them ideal for 
detecting myocardial injury [37] .  
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Figure 2. Schematic Representation of the Cardiac Myofibrillar Thin Filament 
 
Cardiac Troponins Exist in a Structural (bound) Form and in a Free Cytosolic Pool. Cardiac 
Troponins are Released from Monocytes as Complexes or as Free Protein 
 
 
Figure 3. Troponin Complex 
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2.2 TROPONIN ASSAYS 
Immunoassays have been developed to make a distinction between cardiac and skeletal subforms 
of troponin I and of troponin T [38] and because of this the interpretation and comparison of 
troponin levels has been challenging.  There are several cardiac troponin I assays available for 
use compared to one troponin T assay.  The troponin I assays are not standardized leading to 
considerable dissimilarities among procedures [39].  
The heterogeneity of troponin assays necessitates that clinicians know the limitations and 
analytical quality of the assay being used. It is recommended that the detection limit for 
myocardial injury be the concentration that corresponds to the 99th percentile limit of the 
reference distribution in healthy people, (Figure 4) [35].  
 
 
Figure 4. Troponin I in a Health Reference Population and in an Acute Coronary Syndrome 
Population 
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Cardiac troponin immunoassays use two reference ranges to report troponin levels, the 
coefficient of variation and the upper percentile reference limit. The goal is for the coefficient of 
variation (CV) to be ≤10 % at the 99th percentile or three standard deviations above the mean for 
the normal range [40]. The CV is the percent variation in assay results that may be expected 
when the same sample is repeatedly analyzed. The upper percentile reference limit gives the 
upper limit of what may be expected in a healthy, normal adult population.  
Even though the development of cardiac troponin assays with increasing sensitivity 
lowers the number of potentially missed ACS diagnosis, it presents a diagnostic challenge as the 
gains in sensitivity have come at the cost of decreasing specificity [41].  
The VA Pittsburgh Healthcare System performed Troponin I methodology on the Siemens 
Xp and instrument using the Troponin-I Flex reagent cartridge. The CTNI method for the 
Dimension clinical chemistry system with heterogenous immunoassay module as an in-vitro 
diagnostic test is intended to quantitatively measure cTnI levels in human serum and heparinized 
plasma. Lithium heparin plasma is the sample of choice. Specimens are stable for 8 hours when 
at 20-25 degrees Celsius, 2 days at 2-8 degrees Celsius. For longer storage, specimens may be 
frozen at -20 degrees Celsius or colder. This is a highly sensitive colorimetric immunoassay that 
measures cTnI, however, it is not considered a high-sensitivity troponin assay. The 
manufacturers biometric assay reference range: 0.04-0.99ng/mL (negative); 0.10-0.6ng/mL 
(indeterminate); and >0.6ng/mL (positive) (Seimens Healthcare Diagnostics Inc, Deerfield IL). 
2.3 THIRD UNIVERSAL DEFINITION OF MYCOCARDIAL INFARCTION 
In 2012, a Task Force comprised of the European Society of Cardiology (ESC), American 
College of Cardiology Foundation (ACC), American Heart Association (AHA) and the World 
Heart Federation (WHF) [35] released its third universal definition of MI. The new universal 
definition of MI is classified into various types based on clinical, pathological and prognostic 
differences, as well as treatment options, Table 1 [35]. 
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Table 1. Universal Classification of Myocardial Infarction 
 
Type I: Spontaneous myocardial infarction 
Spontaneous myocardial infarction related to atherosclerotic plaque rupture, ulceration, fissuring, erosion, 
or dissection with resulting intraluminal thrombus in one or more of the coronary arteries leading to decreased 
myocardial blood flow or distal platelet emboli with ensuing myocyte necrosis. The patient may have underlying 
severe CAD but on occasion non-obstructive or no CAD. 
Type II: Myocardial infarction secondary to an ischemic imbalance 
In instances of myocardial injury with necrosis where a condition other than CAD contributes to an 
imbalance between myocardial oxygen supply and/or demand, e.g. coronary endothelial dysfunction, coronary 
artery spasm, coronary embolism, tachy-/brady-arrhythmias, anemia, respiratory failure, hypotension, and 
hypertension with or without LVH. 
Type III: Myocardial infarction resulting in death when biomarker values are unavailable 
Cardiac death with symptoms suggestive of myocardial ischemia and presumed new ischemic ECG 
changes or new LBBB, but death occurring before blood samples could be obtained, before cardiac biomarker 
could rise, or in rare cases cardiac biomarkers were not collected. 
Type IVa: Myocardial infarction related to percutaneous coronary intervention (PCI) 
Myocardial infarction associated with PCI is arbitrarily defined by elevation of cTn values >5 x 99th 
percentile URL in patients with normal baseline values (≤ 99th percentile URL) or a rise of cTn values >20% if the 
baseline values are elevated and are stable or falling. In addition, either (i) symptoms suggestive of myocardial 
ischemia, or (ii) new ischemic ECG changes or new LBBB, or (iii) angiographic loss of patency of a major 
coronary artery or a side branch or a persistent slow or no flow or embolization, or (IV) imaging demonstration of 
new loss of viable myocardium or new regional wall motion abnormality are required. 
Type IVb: Myocardial infarction related to stent thrombosis 
Myocardial infarction associated with stent thrombosis or detected by coronary angiography or autopsy in 
the setting of myocardial ischemia and with a rise and/or fall of cardiac biomarkers values with at least one value 
above the 99th percentile URL. 
Type V: Myocardial infarction related to coronary artery bypass grafting (CABG) 
Myocardial infarction associated with CABG is arbitrarily defined by elevation of cardiac biomarker 
values >10 x 99th percentile URL in patients with normal baseline cTn values (≤ 99th percentile URL). In addition, 
either (i) new pathological Q waves or new LBBB, or (ii) angiographic documented new graft or new native 
coronary artery occlusion, or (iii) imaging evidence of new loss of viable myocardium or new regional wall motion 
abnormality. 
 
This definition takes into account the increasing sensitivity of troponin assays that are 
frequently elevated in conditions other than acute MI allowing for the differentiation between 
pathologic MI and benign myocardial injury, (Figure 5) [42]. 
Moreover, in addition to troponin elevation, the detection of MI takes into consideration 
the clinical symptoms, and EKG findings at the time of presentation [35] .  
The clinical features of MI include chest, arm, shoulder, jaw or epigastric discomfort, 
shortness of breath, nausea, diaphoresis, syncope or fatigue that usually lasts more than 20 
minutes and may occur with rest or exertion. The associated ECG changes are usually T wave 
and ST segment changes. It is prudent to consider troponin elevation, ECG changes, and clinical 
presentation when diagnosing MI.  
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Upon hospital admission, the sensitivity of cTnI is less than 45%; however, the 
sensitivity increases to 100% at 6 to 12 hours after admission [43, 44]. Cardiac troponin I levels 
can be detected as soon as 2 to 4 hours after symptom onset with peak values occurring between 
8 to 16 hours after the onset of symptoms and may be present for up to 4 to 14 days [1].   
The use of cardiac troponin I and T levels for the diagnosis of acute MI and the 
prediction of subsequent cardiac events has been well established (Tables 2 and 3),  [45]. While 
troponin I and T elevation reflects myocardial injury, it does not specify the etiology of the 
injury [46, 47]. The diagnostic value of troponin I extends beyond identifying myocardial injury, 
(Figure 6) [42]. Troponin I can provide prognostic information for many other medical 
conditions such as heart failure [48], hypertension [49], hypertrophic cardiomyopathy [50] and 
renal failure [51-53].  The predictive value of an initial cTnI in determining all-cause mortality, 
acute MI, and as a prognostic tool for other medical conditions in the VA Pittsburgh Healthcare 
System is unknown. 
 
Figure 5. Evolution of the Cardiac Troponin Assays and their Diagnostic Cutoffs 
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Table 2. Outcomes for Studies of Troponin T 
 
Table 3. Outcomes for Studies of Troponin I 
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Figure 6. Troponin Kinetics 
2.4 CHRONIC KIDNEY DISEASE 
There is a significant increase in mortality and morbidity from CVD among patients with chronic 
kidney disease (CKD) [54] and CKD has been shown to be an independent risk factor for 
cardiovascular events [55]. Patients with CKD, but not on dialysis, are more likely to die from 
CVD than to progress to renal failure[56, 57]. Premature coronary atherosclerosis is associated 
with CKD particularly in the setting of several chronic renal failure induced risk factors 
including hypertension and lipid disorders [58, 59]. 
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The increased risk of cardiovascular events such as recurrent MI, heart failure, restenosis 
and death, according to most cardiovascular outcome studies, occurs when the serum creatinine 
level is approximately >1.5mg/dL which translates to an eGFR <60mL/min/1.73m2 in the general 
population [60, 61]. 
In 2002, the National Kidney Foundation Kidney Disease Outcomes Quality Initiative 
(NFK-KDOQI) published the first internationally accepted definition and classification of CKD.  
In 2004, this definition was supported by the workgroup, Kidney Disease: Improving Global 
Outcomes (KDIGO). This model encouraged deepened awareness of CKD as a public health 
issue, as well as its importance in research and clinical practice. KDOQI and KDIGO indicated 
that the definition and classification of CKD should be indicative of the patient’s prognosis. This 
stance prompted debate. In 2009, a collaborative meta-analysis to assess the association of eGFR 
and albuminuria to mortality and kidney outcomes and a Controversies Conference was initiated 
by KDIGO. Based on the analysis of 45 cohorts consisting of over 1.5 million subjects that 
represented the general, high-risk and kidney disease populations, it was agreed to retain the 
current definition of CKD and to modify the classification of CKD [62] . 
CKD is defined as a Glomerular filtration rate (GFR) <60ml/min/1.73m2 for ≥ 3 months 
with or without kidney damage or a urinary albumin-to-creatinine ratio >30mg/g. The 
classification of CKD was modified by the addition of the stage of albuminuria, subdivision of 
stage 3 and highlighting the clinical diagnosis. The previous GFR 5-stage classification 
subdivided category 3 (GFR 30-59 mL/min per 1.73m 2) into category 3a (GFR 45-59 mL/min 
per 1.73m 2) and 3b (GFR 30-44 mL/min per 1.73m 2). This change was the result of various risk 
profiles and different outcomes that were supported by the data [63]. Based on the clinical 
diagnosis, stage and other important aspects relevant to the outcome of interest a prognosis can 
be made. 
Kidney damage was defined as structural or functional abnormalities of the kidney ≥ 3 
months, with or without a decrease in the GFR with evidence of markers of kidney damage, such 
as abnormalities of blood, urine or imaging test [64].  Based on the level of GFR, the various 
stages of CKD, stages I through V, are shown in Table 4 [64] .  
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Table 4. Stages of Chronic Kidney Disease 
Stage Description GFR, mL/min per 1.73m2 
I Kidney damage with normal or increased GFR ≥90 
II Kidney damage with mildly decreased GFR 60 to 89 
III Moderately decreased GFR 30 to 59 
IV Severely decreased GFR 15 to 29 
V Kidney failure < 15 or dialysis 
 
The persistent presence of albumin in the urine is recognized as an early sign of renal 
pathology, preceding an actual decline in GFR [65, 66]. An albumin-creatinine ratio (ACR) 
greater than 30mg/g creatinine in a spot urine sample is usually considered abnormal [67].  
In 2012, KDIGO updated the Clinical Practice Guideline for the Evaluation and 
Management of Chronic Kidney Disease, made recommendations regarding the definition and 
classification of CKD. The group retained the diagnostic cut-offs for an ACR ≥30mg/g creatinine 
and GFR of <60mL/min per 1.73m2. The updated definition of CKD was defined as 
“abnormalities of the kidney structure or function, present for >3 months, with implications for 
health (not graded)”[56, 68]. It is important to note, debate existed among the work group 
members regarding making recommendations in the setting of a weak level of evidence. 
However, the group opted to provide guidance instead of remaining quiet to assist the healthcare 
provider with making clinical decisions [56]. 
The guideline evidence was graded based on the Grading of Recommendations 
Assessment, Development and Evaluation system (GRADE) [69]. To emphasize areas of 
uncertainty in clinical practice and important concepts, the workgroup made proposals based on 
consensus even when the quality of the evidence was low. The addition, “with implications for 
health,” takes into consideration that while different anomalies of renal function and structure 
may be present, not all will have health consequences. 
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In the setting of CKD the interpretation of cardiac biomarkers, cTnI and cardiac troponin 
T (cTnT) can prove to be difficult, Table 5, [70]. In studies using first generation troponin 
assays, up to 71% of cTnT and approximately 7% of cTnI were elevated in the absence of 
myocardial ischemia. Even with the development of newer assays, cTnT remains more elevated 
than cTnI in patients with CKD and without evidence of myocardial necrosis with up to 53% of 
patients with elevated cTnT and 15% cTnI respectively [71-73].  
According to the American College of Cardiology Foundation Task Force 2012 Expert 
Consensus Document on Practical Clinical Considerations in the Interpretation of Troponin 
Elevations levels of  elevated troponin in patients with reduced renal function remains somewhat 
controversial [74]. Troponin I levels after an MI appear to be similar in patients with end-stage 
renal disease as well as those with normally functioning kidneys [75], whereas the troponin T 
levels are broken down into smaller particles that are small enough to be filtered by the kidney 
thereby detected by the assay which may partially account for the elevations of troponin T seen 
in patients with renal disease [76]. 
The National Academy of Clinical Biochemistry practice guidelines recommend the use 
of troponin in all CKD patients with suspected ACS. The dynamic changes seen in troponin 
levels among patients with end-stage renal disease should be ≥20% in the 6 to 9 hour window 
after presentation to meet criteria for MI [77].  
No clear mechanism exists to explain this increase but several have been proposed. In 
addition to CKD as a mechanism for elevated levels of circulating cardiac troponins precursors 
to heart failure such as left ventricular hypertrophy (LVH), myocarditis [78, 79] and epicardial 
coronary disease [80] may act as a substrate.  
The physiological relations between CKD and HF are multifaceted and causally 
connected [81] Many people with HF also have CKD, usually marked by a decrease in GFR.  
The risk of developing HF is significantly increased with declining renal function [82].     
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Table 5. SOE for Diagnostic Accuracy and Prognostic Value of Elevated Troponin Level in 
Patients with CKD and Suspected ACS 
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2.5 HEART FAILURE 
Circulating levels of cardiac troponin have been shown to predict mortality in patients with HF. 
According to the 2009 Focused Update [83] Incorporated into the American College of 
Cardiology and American Heart Association’s (ACC/AHA) 2005 Guideline Update for the 
Diagnosis and Management of Chronic HF in Adults [84], HF is defined as a disorder that 
impairs the ability of the ventricle to fill with or eject blood secondary to a functional or 
structural cardiac abnormality.  
Various hemodyamic and neurohormonal changes lead to progressive myocyte damage 
via apoptic cell death and necrosis resulting in fibrosis that may contribute to progressive cardiac 
dysfunction and left ventricular remodeling [85, 86]. 
HF is a major and growing health problem in the United States [87].  An estimated 5.1 
million Americans ≥20 years of age have HF. The prevalence of HF is projected to increase from 
2013 estimates by 25% and the cost will increase by approximately 120% to 70 billion by 2030 
[6]. It is classified in to 4 stages (Table 6 [88]) that emphasize both the development and 
progression of the disease.  
Table 6. Stages of Heart Failure 
Stage A Stage B Stage C Stage D 
At high risk for HF but 
without structural heart 
disease or symptoms of 
heart failure. 
Structural heart disease 
but without signs or 
symptoms of HF. 
Structural heart disease 
with prior or current 
symptoms of HF. 
Refractory heart failure 
requiring specialized 
interventions 
 
Stages A and B are used to describe those people who have risk factors for developing 
HF but do not currently have HF. Risk factors included hypertension, metabolic syndrome, 
obesity, CHD or diabetes. Stage A describes people with risk factors with preserved ejection 
fraction, hypertrophy or structural distortion. Stage B describes people who are asymptomatic 
but have evidence of impaired left ventricular function and/or left ventricular hypertrophy 
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(LVH). Stage C identifies people with current or past symptoms of HF in the setting of structural 
heart disease. Lastly, Stage D consists of people with refractory HF who may be eligible for 
specialized advanced treatments or end-of-life care [89-91]. 
Circulating levels of cTnI and cTnT are associated with an increased risk of morbidity 
and mortality in both acute and chronic HF [92].  Elevated cardiac troponin levels are also 
detectable in patients with HF in the absence of unstable coronary syndromes and may act as a 
marker for the progression of HF [93] The magnitude of troponin elevations in patients with HF 
has been associated with disease severity and a worse prognosis [94, 95]. 
 Troponin elevations may be seen in acute and chronic HF [93, 96] and may have broad 
implications for the treatment, development of new treatment options, prognosis and 
comprehension of underlying physiology [92].  The levels of cardiac troponins in HF are 
generally lower than those seen with ACS and lack of the characteristic rise and fall pattern [4].  
The Acute Decompensated Heart Failure National Registry (ADHERE) is a large 
multicenter prospective registry that was designed to collect data on patients hospitalized with 
acute decompensated heart failure beginning at the point of entry and concluded with the 
patients’ discharge, transfer or in-hospital death thus allowing for evaluation of the management 
of heart failure patients under “real world” conditions [97, 98]. The ADHERE study showed a 
significant increase in in-hospital mortality (8.0% vs. 2.7%, p < 0.0001), in patients with acute 
HF, with an elevated cardiac troponin level defined as cardiac troponin I level of 1.0 μg per liter 
or higher or a cardiac troponin T level of 0.1 μg per liter or higher by any assay during the time 
of hospitalization [99], Figure 7. 
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Figure 7. In-Hospital Mortality According to Troponin I or Troponin T Quartile 
P<0.001 by the chi-square test for all comparison 
 
The ADHERE investigators reported in an analysis of >105,000 cases, only 6.2% had a 
troponin level above the upper reference limit corresponding to the 10% imprecision whereas 
75% of cases had a detectable troponin level. Troponin levels above the upper reference limit 
were associated with more severe HF [85-87].  
In patients with chronic stable HF measurable or elevated circulating troponin levels are 
common [100, 101]. The Valsartan Heart Failure Trial (Val-HeFT) was a multicenter, 
randomized, placebo-controlled, double-blind, parallel-arm trial that examined the effects of 
valsartan, an angiotensin blocker vs. placebo in 5010 patient with stable symptomatic HF with 
left ventricular dysfunction [102].  In 4053 chronic heart failure patients, the troponin level using 
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a conventional troponin assay was reported to be positive in 10.4% compared to 92% using the 
highly-sensitive troponin assay in the Val-HeFT trial [82]. 
While cardiac troponin levels in HF lack the characteristic rise and fall pattern seen in 
patients with ACS and are lower [103], they have been shown to predict adverse outcomes in 
acute [104] and chronic HF [48, 105]. HF is the final phase of hypertensive heart disease (HHD). 
The pathophysiology of HHD is a progressive process that begins with hypertension followed by 
LVH and ultimately to HF [106].    
2.6 HYPERTENSION 
Hypertension is a major public health concern responsible for considerable morbidity and 
mortality [107].  One third of adults or approximately 77.9 million people in the United States 
have high blood pressure and about 6% of Americans have undiagnosed hypertension. The 
estimated direct and indirect cost for high blood pressure in 2009 $51 billion with projections to 
increase to $343 billion by 2030 [6, 9, 108] .  
The prevalence of hypertension is projected to increase by 7.2% from 2013 estimates by 
2030 [6]. African Americans have among the highest prevalence of high blood pressure in the 
world and it continues to rise increasing from 35.8% in 1988 to 41.4% in 2002 [109]. 
The death rate from high blood pressure has increased by 17.1% from 1999-2009 [6, 7]. 
The age-adjusted mortality rate from NHANES I and II compared hypertensive and non-
hypertensive people revealed a decrease among people with hypertension of 4.6/1000 person-
years compared to 4.2/1000 person-years among people without hypertension [110]. 
According to the Joint National Committee on Prevention, Detection, Evaluation and 
Treatment of High Blood Pressure (JNC-7) published in 2003 there is a continuous relationship 
between blood pressure and risk of cardiovascular events. This relationship is continuous, 
consistent, and independent of other risk factors. The risk of experiencing a heart attack, HF, 
stroke, and kidney disease increases as blood pressure rises[111]. 
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For people 40–70 years of age, each increment of 20 mmHg in systolic blood pressure or 
10 mmHg in diastolic blood pressure doubles the risk of CVD across the entire range of blood 
pressure from 115/75 to 185/115 mmHg [112] .  
Patients with prehypertension are at increased risk for progression to hypertension; those 
in the 130–139/80–89 mmHg BP range are at twice the risk to develop hypertension as those 
with lower hypertension as those with lower values, (Table 7) [111]. 
In 2014, The Joint National Committee on Prevention, Detection, Evaluation and 
Treatment of High Blood Pressure (JNC-8) was published. However, unlike previous JNC 
reports, JNC-8 was not supported by any major American or European cardiovascular 
organization given the prolonged time interval between JNC publications [111, 113, 114].  This 
time delay led to other hypertensive guidelines being crafted by other key groups, (Table 8),  
[115]. 
The classic paradigm of HHD is that the left ventricle thickens as a consequence of 
elevated blood pressure as an adaptive mechanism to decreased myocardial wall stress ultimately 
resulting in a transition to failure whereby the left ventricle dilates and the ejection fraction 
decreases [116].  
The ability to predict the development of CVD in patients with hypertension is valuable. 
Several studies have shown that apoptotic cardiomyocytes are associated with hypertension [117, 
118].  Yet few studies have assessed ongoing myocardial damage in vivo and its relationship to 
the prognosis of hypertensive patients. 
A study by Setsuta et al provided the first evidence that hypertensive patients with 
elevated cTnT have a significantly higher incidence of future cardiovascular or cerebrovascular 
events [119]. Values for cumulative freedom from cardiovascular or cerebrovascular event rates 
were significantly lower in patients with than without elevated cTnT,  (Table 9) [119].  
Hypertension is a precursor to left ventricular dysfunction, a significant antecedent in the 
development of heart failure with preserved ejection fraction [120, 121], as well as a major risk 
factor for other cardiovascular diseases [122].  
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Table 7. JNC 7 Classifications and Management of Blood Pressure for Adults 
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Table 8. Summary of Major Hypertension Guidance Documents 
 
 
 
Table 9. Cardiovascular or Cerebrovascular Events During Follow-up Period in Patients with cTnT 
and ≥ and 0.02ng/Ml 
 
   
 cTnT ≥0.02ng/mL 
(n=15) 
cTnT <0.02ng/mL 
(n=161) 
Heart failure, n (%) 5 (33%) 10 (6%) 
Cerebral infarction, n (%) 4 (27%) 7 (4%) 
Acute coronary syndrome, n (%) 2 (13%) 1 (1%) 
Aortic dissection 1 (7%) 2 (1%) 
Cerebral hemorrhage, n (%) 0 (0%) 1 (1%) 
Transient ischemic attack 0 (0%) 1 (1%) 
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2.7 LEFT VENTRICULAR HYPERTROPHY 
In patients with hypertension, with the exception of age, LVH is the strongest predictor of 
adverse cardiovascular outcomes and is an independent risk factor for HF, sudden death, CHD 
and stroke [123, 124].  
The natural history of LVH is heterogeneous, while some individuals do not experience 
difficulty others go on to develop heart failure. The progression from hypertension to concentric 
left ventricular hypertrophy to heart failure is a vital component in this pathway. Biomarkers 
may help to identify asymptomatic individuals at high risk of disease progression and to develop 
treatments that prevent disease transition [90, 125].  
Pathophysiologic changes that occur in hypertensive LVH consists of an increase in the 
cardiomyocyte size, changes in the extracellular matrix [126], buildup of fibrosis and 
intramyocardial vascular abnormalities such as perivascular fibrosis and medial hypertrophy 
[127, 128]. Decreases in blood pressure have been shown to reduce LVH  [129]. 
LVH is diagnosed using EKG, echocardiography (ECHO) or cardiac magnetic resonance 
imaging (MRI).  Electrocardiography is the most readily available and also the most economic.  
A systematic review of 21 studies [130] revealed that various voltage criteria in addition 
to several other factors that may be taken into consideration when determining the presence of 
LVH by EKG such as ST-T wave abnormalities, left atrial abnormalities or the duration of the 
QRS complex were found to be less sensitive than specific [131, 132]. 
The issue of decreased sensitivity for the diagnosis of LVH via EKG, which results in an 
under-diagnosing of LVH, is related to the method of measuring the electrical cardiac activity on 
the skin surface to predict the left ventricular mass as this is affected by air, fluid, adipose tissue 
as well as age and race [133]. Although the EKG has decreased sensitivity, it is still used in the 
diagnosis and management of LVH.   
The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study showed 
regression of LVH in response to Losartan along with improved cardiovascular outcomes, 
independent of blood pressure, using the Cornell criteria or the Sokolow-Lyon index methods for 
diagnosing LVH on EKG [134] .   
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ECHO is more sensitive than electrocardiography in determining the presence of LVH 
and LVH diagnosed by ECHO, is a precursor to premature mortality across all races, ages and 
genders [135, 136]. Even after adjustment for possible confounders, there is growing evidence of 
an association between an increase in left ventricular mass and higher rates of cardiovascular 
morbidity and mortality [137, 138].  
The gold standard for measuring LVH is cardiac MRI as it is more accurate and 
reproducible [139]. However, the use of cardiac MRI is restricted secondary to the high cost and 
limited availability [140].  
LVH screening programs have been mired by low LVH prevalence rates, decreased 
sensitivity of electrocardiography and the use of echocardiography as a screening tool is cost 
prohibited [141]. The Dallas Heart Study suggested by adding validated markers associated with 
LVH such as highly sensitive troponin T and amino-terminal B-type natriuretic peptide to the 12-
lead EKG may be able to function as an inexpensive screening tool for LVH in selected 
populations [142] .  
In the general population, there is a strong correlation between circulating levels of high 
sensitivity cardiac troponin T and cardiac structure abnormalities such as left ventricular 
hypertrophy [143]. Identification of biological pathways that provide INFORMATION related to 
the progression from left ventricular hypertrophy to heart failure and the biomarkers that 
represent these pathways may assist with the identification of individuals considered to be a high 
risk for adverse events and to develop therapeutic modalities to prevent disease progression 
[144].  
cTnT is one of the cardiac biomarkers released in response to increased LVH and wall stress  
[78] in the general population and has been strongly associated with incident heart failure [145, 
146] and mortality [145].  However the data regarding the impact of minimally elevated troponin 
T are lacking. 
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2.8 DIABETES 
Diabetes is a major risk factor for CHD and stroke [147]. The prevalence of diabetes for all age 
groups is projected to be 4.4% in 2030 compared to an estimated 2.8% in 2002 [6]. According to 
the 2014 National Diabetes Statistics Report, 29.1 million people or 9.3% of the U.S. population 
have diabetes, this reflects 21 million people who have been diagnosed with diabetes and 8.1 
million people undiagnosed [148].  
The Framingham Heart Study has shown that diabetes continues to be associated with 
incremental cardiovascular disease risk, despite improvements in cardiovascular morbidity and 
mortality. There was a 50% reduction in the rate of incident cardiovascular events among adults 
with diabetes; however, the absolute risk of cardiovascular disease remained 2-fold greater than 
among people without diabetes [149]. 
Patients with type 2 diabetes (T2DM) without prior CVD [150] and an elevated hemoglobin 
A1C level have been found to have increased hs-cTnT levels [151]. Nevertheless, the clinical 
interpretations of this are unclear. The Women’s Health Study showed that a detectable level of 
hs-TnT in diabetic women was associated with increased cardiovascular morbidity and mortality 
[150]. In contrast, a study by Hallen et al. did not predict adverse events in diabetic patients with 
an elevated hs-TnT over a 2 year follow-up phase [152].  hs-cTnI is a more sensitive assay for 
subtle myocardial damage given the higher proportions of patients without diabetes have a 
detectable level of hs-cTnI when compared to hs-TnT [153]. The data are lacking in regards to 
the predictive value of hs-cTnI in patients with type 2 diabetes.  
2.9 SUMMARY 
The overall significance of this proposed descriptive study is to provide baseline data to 
determine whether the initial level of cTnI >0.04ng/mL provides additional information 
regarding the identification and management of ACS, all-cause mortality, and HF readmissions 
within one year of discharge in the time frame of interest, fiscal year 2010. In addition to 
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determine the value of an initial troponin level in patients without MI on the presence of HF, 
diabetes, renal disease, hypertension and LVH as data in this area are lacking. 
The potential of this study is to identify patients with acute MI in a timelier manner, 
particularly because previous studies have shown that about 67% of Veterans wait approximately 
12 hours prior to presenting to the VA Healthcare System with symptoms consistent with a heart 
attack, compared to 18% of Medicare recipients. 
The ability to identify and intervene early on the natural history of these diseases may indeed 
decrease the clinical squeal as well as readmissions, length of stay, improve clinical outcomes, 
decrease mortality/morbidity and improve quality of life and provide cost savings. 
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3.0  SYNOPSIS AND METHODS 
This is a retrospective record review at the VA Pittsburgh Healthcare System to assess the 
predictive value of the initial cTnI level in determining acute MI, all-cause mortality and the 
prognostic value of troponin levels in patients without acute MI in determining the presence of 
several chronic diseases by utilizing the computerized patient records system (CPRS). The data 
warehouse and the daily automated troponin list will be used to identify patients who had a 
troponin level drawn during fiscal year 2010, the timeframe of interest in this study. Patients will 
be followed for 365 days post-discharge to determine if mortality and/or acute MI has occurred. 
The prognostic value of the initial cTnI level >0.04ng/mL in those patients without an acute MI 
will be evaluated.  
The primary analysis will exclude individuals who died during the hospitalization, had a 
length of stay >30 days, transferred to a different facility or were discharged home with hospice. 
The study is descriptive so there is no comparison group. 
The subjects will be placed into one of two groups according to the instrument’s 
analytical sensitivity. Either ≥0.04ng/mL or <0.04ng/mL based on the initial cTnI result. The 
group with levels ≥0.04ng/mL will be further categorized by the manufacturers biometric assay 
reference range: 0.04-0.099ng/mL (negative); 0.10-0.6ng/mL (indeterminate); and >0.6ng/mL 
(positive).  
The data will be stored in an Excel spreadsheet for future import into STATA statistical 
software package for data analysis.  
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3.1 DEFINITION OF VARIABLES 
The definitions of the outcome variables for this study are described by the Center for Medicare 
and Medicaid Services ICD-9 codes. The outcome variables will be treated as dichotomous and 
are as follows: acute MI is defined as the initial episode of care (410.01-410.20) for STEMI and 
410.0 -410.72 for NSTEMI; HF codes 428.1-428.32; CKD codes 585.1-585.9; LVH 429.3; 
hypertension  codes 401-405 and diabetes code 250.  
Categorical variables during the admission of interest include the following: Sex is 
defined as male or female; race is defined as Caucasian, African American, Asian, Other or 
Unknown; Electrocardiogram (EKG) is defined as Other, STEMI or NSTEMI; Ejection fraction 
(EF) is categorized in increments of 10, starting with an EF >55%, 45-54%, 25-34%, <24% and 
unknown; smoking status (SMK) is categorized into never smoker, current smoker, previous 
smoker and unknown;  MODE is the testing modality used to obtain the ejection fraction  and 
includes echocardiogram, stress test,  cardiac catheterization or multiple gated acquisition scan 
(MUGA); (TOT) is the date of testing when the ejection fraction was obtained and is defined as 
before, during, after the admission of interest or unknown.  
Continuous variables during the admission of interest include the following: age in years; 
body mass index (BMI); length of stay (LOS) reported in days; time to presentation (TTP) the 
time in hours from symptom onset until presentation for medical care; troponin (TRO) is the 
initial troponin level reported as mg/mL with a manufacturers reference of 0.04- >0.60ng/mL; 
brain natriuretic peptide (BNP) reported as pg/mL with a reference range as 5-100 pg/mL; serum 
creatinine (CREAT) reported in mg/dL with a reference range of 0.50-1.20mg/dL; estimated 
glomerular filtration rate (eGFR) reported as mL/min/1.732; serum albumin (ALB) reported as 
gm/dL with a reference range of 3.2 -5.5 gm/dL.  
The goals of this study are to examine all patients admitted with cTnI levels drawn and 
specifically levels >0.04 ng/mL to determine if the initial troponin at very low levels is 
associated with all-cause mortality, acute MI, congestive heart failure readmission at one year 
post discharge, as well as simultaneous diagnosis of the chronic diseases of interest (HTN, HF, 
LVH, CKD) at the time of the initial troponin during the admission of interest in fiscal year 2010 
or with the potential diagnosis of the chronic disease of interest at 365 days post discharge.  
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The cardiac troponin-I (cTnI) method used at the VA Pittsburgh Healthcare System is 
performed on the Siemens Dimension® XPAND machine using the Troponin-I Flex® reagent 
cartridge. This is a highly sensitive, colorimetric immunoassay that measures cardiac troponin-I, 
however, it is not considered a high-sensitivity troponin assay. 
The initial troponin level will be used as the reference hospitalization. Patients will be 
followed retrospectively after reference hospital discharge to determine 365-day occurrence of 
acute MI, HF admission, all-cause mortality and certain chronic diseases (hypertension, LVH, 
diabetes and CKD) based on ICD-9 codes.  
The data will be described using means +/- standard deviation for normally distributed 
variables and median (interquartile range) for non-normally distributed variables. Numbers and 
percents will be used for categorical variables. The study population demographics will be 
compared (age, race, gender) between the two troponin groups, troponin >0.04mg/dL and 
troponin <0.04mg/mL.   
For these comparisons, t-tests (or Mann-Whitney) will be used for continuous variables 
and Chi-square tests (or Fisher’s exact) if the data are categorical.  If a statistically significant 
difference is detected between the two groups for a certain variable, the variable will be included 
in an adjusted model when assessing the predictive ability of the troponin groups.  In addition, 
known confounders from the literature such as age, race and gender will also be included in 
adjusted models. Other potential confounders will be investigated as needed. 
The first hypothesis will assess whether the initial troponin level is a predictor of all-
cause mortality. Logistic regression will be used to calculate the odds ratio (OR) and 95% 
confidence intervals (CI) of experiencing an event by serum, troponin level. The group with 
troponin I levels <0.04 will form the referent group. 
The second part of the initial hypothesis is to determine of the initial troponin level is a 
predictor of acute MI. Logistic regression will be used to calculate the OR (95% CI) of AMI by 
troponin. AMI will be defined by ICD-9 codes from 31 days after hospital discharge from the 
reference hospitalization.   
The second hypothesis will assess whether there is an association between the initial cTnI 
level >0.04 ng/mL and HF admission. HF admission will be defined by ICD-9 codes for 31 days 
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after hospital discharge from the reference hospitalization. Logistic regression will be used to test 
if there is a difference in heart failure admissions between the two troponin groups. We will also 
attempt to assess whether a statistically significant interaction exists between troponin and acute 
MI (yes/no). 
The third hypothesis will assess whether there is an association between the initial cTnI 
level >0.04 ng/mL and other chronic medical conditions such as diabetes, hypertension, LVH 
and CKD.  All chronic medical conditions considered will be defined by ICD-9 codes, from 31 
days after hospital discharge from the reference hospitalization. Logistic regression will be used 
to test whether there is a difference in the presence of diabetes, hypertension, LVH and CKD 
between the two troponin groups. We will also attempt to assess whether a statistically 
significant interaction exists between troponin and acute MI (yes/no).   
Sample size computations are not necessary as all patients are included within the time frame 
of interest, fiscal year 2010. Since effect size is not hypothesized an estimate of power is not 
indicated given it is a descriptive study.  
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4.0  SPECIFIC AIMS 
I propose to carry out a retrospective cohort study at the VA Pittsburgh Healthcare System 
University Drive Campus to assess the predictive value of the initial concentrations of cTnI 
>0.04ng/mL in determining all-cause mortality, MI, HF readmission at one post discharge from 
initial troponin during admission of interest in fiscal year 2010 and whether the initial 
concentration of cTnI are predictive of other medical conditions such as diabetes, hypertension, 
left ventricular hypertrophy and kidney disease by utilizing the automated daily troponin list, the 
data warehouse and the computerized patient records data (CPRS).  
4.1 SPECIFIC AIM 1 
Determine the association of initial cTnI levels of >0.04ng/mL on all-cause mortality and acute 
MI at one year post-discharge from the admission of interest during fiscal year 2010. 
4.1.1 Hypothesis 1 
cTnI can be detected as soon as 2 to 4 hours after symptoms and even mild elevations in 
conventional troponin assays have been associated with an increase in mortality rates. However, 
67% of veterans admitted to the VA Healthcare Systems waited more than 12 hours after onset 
of MI symptoms before presenting to the hospital [37]. The predictive value of the initial cardiac 
troponin I level >0.04ng/mL is not well studied. 
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4.2 SPECIFIC AIM 2 
Determine the association of initial cTnI levels on HF readmission at one year post discharge 
from the admission of interest. 
4.2.1 Hypothesis 2 
cTnI levels in acute and chronic HF have been shown to predict adverse outcomes with troponin 
levels above the upper reference limit associated with more severe HF. The predictive value of 
the initial cTnI level >0.04 ng/mL on future HF admissions is unknown.  
4.3 SPECIFIC AIM 3 
Determine the association of the initial cTnI level >0.04 ng/mL with other chronic medical 
conditions such as diabetes, hypertension, LVH and CKD. 
4.3.1 Hypothesis 3 
The presence of circulating cTnI levels may have significant predictive value in the absence of 
MI. Troponins provide prognostic information for many medical conditions. The predictive 
value of an initial cardiac troponin I level >0.04ng/mL as a predictor for chronic medical 
conditions in the VA Healthcare System is unknown.  
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5.0  RESULTS 
The analytic flow charts for hypothesis 1 and 2 and hypothesis 3 are shown in Figure 8 and 
Figure 9.  As noted in the methods, we identified all patients with inpatient admissions during 
2010 who had cTnI assessed during their initial hospital admission.  We excluded those who had 
an incident AMI during initial hospitalization, died in the hospital, were discharged from the 
emergency room or had a length of stay >30 days or were transferred to another facility. After 
exclusions, in total 2,129 patients were admitted to the VA Pittsburgh Healthcare System in 2010 
with a serum cTnI level drawn.  Of these, 706 (33.3%) patients had an initial troponin level 
>0.04ng/mL, (Table 10). Subjects with a higher serum troponin I, were significantly older, had a 
longer length of stay, were more likely to be male, had higher serum creatinine, lower eGFR and 
higher BNP.  Differences in BNP were especially large with the median BNP among patients 
with serum troponin I levels >0.04ng/mL of 589.3 compared to 172 in patients with troponin I < 
0.04ng/mL.  There was no difference in race or BMI by level of troponin I measured on hospital 
admission.  Patients with elevated serum troponin I were, however, less likely to be a current 
smoker. 
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Figure 8. Initial Highly Sensitive cTnI Level as Predictor of Acute Coronary Syndrome and CHF 
Readmission at one year post-discharge, Hypotheses 1 and 2 
 
 
Figure 9. Initial Highly Sensitive cTnI Level as Predictor of Heart Failure, Diabetes, Chronic 
Kidney Disease and Left Ventricular Hypertrophy - Initial Highly Sensitive cTnI Level as predictor 
of Acute Coronary Syndrome and CHF Readmission at one year discharge – Hypothesis 3 
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Table 10. Characteristics of Eligible Subjects by Initial Troponin Category (n=2,129) 
 
Variable 
Initial Troponin 
<0.04 
n=1423 
Initial Troponin >0.04 
n=706 
Total 
N=2129 
p-value$ n (%) n (%) n (%) 
Age,  mean (SD) 62.33 (13.14) 70.11 (11.82) 64.91 (13.23) <0.00001 
Initial Troponin, mean (SD) 0.01 (0.01) 0.87 (4.40) 0.30 (2.57) -- 
Length of Stay, mean (SD) 4.43 (5.07) 
n=855 
5.56 (5.14) 
n=562 
4.91 (5.17) 
n=1417 <0.0001 
Gender  n (%) 
Female 
Male 
98 (6.9) 
1325 (93.1) 
17 (2.4) 
689 (97.6) 
115 (5.4) 
2014 (94.6) 
<0.0001 
Race  n (%) 
White 
Black 
Other 
Unknown/Missing 
971 (68.2) 
313 (22.0) 
15 (1.1) 
124 (8.7) 
499 (70.7) 
144 (20.4) 
10 (1.4) 
53 (7.5) 
1470 (69.0) 
457 (21.5) 
25 (1.2) 
177 (8.3) 
0.502* 
Smoking (yes)   n(%)  711 (50.0) 284 (40.2) 995 (46.7) <0.0001 
Biological Variables 
BMI, mean (SD) kg/m2 29.95 (8.18) 
n=895 
29.42 (8.88) 
n=538 
29.75 (8.45) 
n=1433 
0
.434 
Creatinine, median (IQR) 
(mg/dl) 
1.10 (0.60) 
n=536 
1.49 (1.20)  
n=358 
1.04 (0.43)  
n=894 <0.00001
# 
eGFR, mean 
(SD)mL/min/1.732 
86.56 (29.91) 
n=536 
70.96 (29.47) 
n=358 
80.31 (30.68) 
n=894 <0.0001 
Albumin, mean (SD)(g/dL) 3.22 (0.57) 
n=197 
3.15 (0.68) 
n=161 
3.19 (0.62) 
n=358 0.267 
BNP, median (IQR)(pg/ml) 172.1 (268.5) 
n=299 
589.3 (633.3) 
n=296 
193 (458.0) 
n=575 <0.00001
# 
SD=standard deviation; IQR=interquartile range; $ - p-values based on t-tests or chi-square tests unless otherwise 
noted; * Fisher’s exact test; #  Mann-Whitey test 
5.1 HYPOTHESIS 1 
Hypothesis 1 tests the research question whether there is an association between initial cTnI level 
and all-cause mortality at 365 days post discharge and whether this association differs by 
prevalence of ACS.  Over the one year of follow-up 89 (12.6%) with elevated cTnI levels died 
compared to 58 (4.1%) among those with cTnI <0.04 ng/mL, (Table 11).  In the unadjusted 
model, patients with an initial cTnI level >0.04ng/mL were 3.39 (95% CI; 2.40, 4.79) times more 
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likely to die within one year compared to those with levels <0.04ng/mL, (Table 12).  These 
associations were attenuated slightly in models adjusting for age, race, sex but remained 
statistically significant. In the final model additionally adjusting for cigarette smoking and renal 
function, patients with an initial troponin level >0.04ng/mL had a two-fold increased risk of 
dying within one year after their hospitalization. 
Of the 2,129 patients, 588 (27.6%) had a diagnosis of ACS, (Table 11).  In both patients 
with or without ACS, patients with initial troponin levels >0.04ng/mL were more likely to die, 
11.1% versus 3.5% in those with ACS and 13.5% versus 4.3% in those without ACS, (Table 11).  
Logistic regression results showed increased odds of dying within 365 days among subjects with 
and without ACS, (Table 13).  In the fully adjusted models (age, race, sex, smoking and eGFR), 
patients with ACS and a serum troponin level >0.04ng/mL were 3.81(95% CI; 1.62, 8.96) times 
more likely to die.  Similarly, among patients without ACS, patients with elevated initial 
troponin level were, 2.05 (95% CI; 1.23, 3.41) times more likely to die within 365 days of initial 
admission.  The interaction between ACS and serum troponin levels was not significant 
(unadjusted model, p interaction=0.914; fully adjusted model, p interaction=0.21). 
5.2 HYPOTHESIS 2 
The second hypothesis of this dissertation examines whether there is an association 
between initial troponin level and MI and HF readmission among patients who were alive 365 
days after discharge.  A total of 1,982 (93%) of patients were alive 365 days post discharge, 
(Table 11).  Of these 35 patients who experienced a MI, 5.7% had a troponin level >0.04ng/mL 
compared to 1.2% with lower troponin levels.  Indeed, patients with troponin levels >0.04ng/mL 
were more than 5.46 times (95% CI; 2.70, 22.0) more likely to experience an incident MI even 
after adjusting for age, race, sex, smoking status and renal function, (Table  12). 
Of those 1,982 patients alive at 365 post discharge only 11 patients were readmitted for 
heart failure, but there was no difference by initial troponin levels (Tables 11 and 12). 
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Table 11. Summary of Results for Hypothesis 1. 2 1d 3:  Number of Patients with an Event by 
Serum Troponin Level at Admission. Outcomes within 365 days of Post Discharge 
 
Outcome 
Initial Troponin 
<0.04ng/mL 
n (%) 
Initial Troponin 
>0.04 ng/mL 
n (%) 
 
p-value* 
Hypothesis 1a:  Is there an association between the initial troponin level and all-cause mortality at 365 post 
discharge 
Mortality 
Dead 
Alive 
58 (4.1) 
1365 (95.9) 
89 (12.6) 
617 (87.4) 
<0.0001 
Hypothesis 1b:  Is there an association between the initial troponin level and all-cause mortality at 365 post 
discharge with and without Acute Coronary Syndrome (ACS) 
With ACS 
Mortality 
Dead 
Alive 
11 (3.5) 
307 (96.5) 
30 (11.1) 
240 (88.9) <0.0001 
Without ACS 
Mortality 
Dead 
Alive 
475 (4.3) 
1058 (95.8) 
59 (13.5) 
277 (86.5) 
<0.0001 
Hypothesis 2a:  Is there an association between the initial troponin level and myocardial infarction among 
patients who were alive 365 post discharge 
Myocardial Infarction 
Yes 
No 
16 (1.2) 
1349 (98.8) 
35 (5.7) 
582 (94.3) 
<0.0001 
Hypothesis 2b:  Is there an association between the initial troponin level and heart failure readmission among 
patients who were alive 365 post discharge 
Readmit for Coronary Heart Failure 
Yes 
No 
7 (0.5) 
1358 (99.5) 
4 (0.6) 
613 (99.4) 
0.747# 
Hypothesis 3:  Is there an association between the initial troponin level and selected chronic medical 
conditions among patients without ACS and who were alive 365 post discharge 
Heart Failure 
Yes 
No 
222 (21.0) 
836 (79.0) 
185 (49.1) 
192 (50.9) 
<0.0001 
Diabetes 
Yes 
No 
452 (42.7) 
606 (57.3) 
195 (51.7) 
182 (48.3) 
0.003 
Hypertension 
Yes 
No 
871 (82.3) 
187 (17.7) 
345 (91.5) 
32 (8.5) 
<0.0001 
Left ventricular hypertrophy 
Yes 
No 
72 (6.8) 
986 (93.2) 
56 (14.9) 
321 (85.2) 
<0.0001 
Chronic kidney disease 
Yes 
No 
202 (19.1) 
856 (80.9) 
146 (38.7) 
231 (61.3) 
<0.0001 
Any of the above chronic medical 
conditions 
Yes 
No 
 
 
904 (85.4) 
154 (14.6) 
 
 
361 (95.8) 
16 (4.2) 
<0.0001 
* based on Chi-square test 
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Table 12. Results of Logistic Regression Models for Outcomes Within 365 Days of Post Discharge 
Outcome OR 95% CI p-value*
Hypothesis 1a:  Is there an association between the initial troponin level and all-cause mortality at 365 post 
discharge 
Unadjusted model 
Initial Troponin 
<0.04 
0.04+ 3.39 2.40-4.79 
<.0001 
Adjusted for age, race, sex 
Initial Troponin 
<0.04 
0.04+ 2.61 1.79-3.81 
<.0001 
Adjusted for age, race, sex, smoking and eGFR 
Initial Troponin 
<0.04 
0.04+ 2.31 1.52-3.52 
<.0001 
Hypothesis 1b:  Is there an association between the initial troponin level and all-cause mortality at 365 post 
discharge with and without Acute Coronary Syndrome (ACS) 
With ACS 
Unadjusted 
Initial Troponin/ACS 
<0.04 
0.04+ 3.49 1.71-7.10 
.001 
Adjusted for age, race, sex 
Initial Troponin/ACS 
<0.04 
0.04+ 3.37 1.60-7.11 
.001 
Adjusted for age, race, sex, smoking and eGFR 
Initial Troponin/ACS 
<0.04 
0.04+ 3.81 1.62-8.96 
.002 
Without ACS 
Unadjusted 
Initial Troponin/ACS 
<0.04 
0.04+ 3.52 2.36-5.26 
<.0001 
Adjusted for age, race, sex 
Initial Troponin/ACS 
<0.04 
0.04+ 2.45 1.56-3.86 
<.0001 
Adjusted for age, race, sex, smoking and eGFR 
Initial Troponin/ACS 
<0.04 
0.04+ 2.05 1.23-3.41 
.006 
Hypothesis 2a:  Is there an association between the initial troponin level and myocardial infarction among 
patients who were alive 365 post discharge 
Unadjusted model 
Initial Troponin 
<0.04 
0.04+ 5.07 2.78-9.23 
<.0001 
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Outcome OR 95% CI p-value*
Adjusted for age, race, sex 
Initial Troponin 
<0.04 
0.04+ 5.27 2.73-10.14 
<.0001 
Adjusted for age, race, sex, smoking and eGFR 
Initial Troponin 
<0.04 
0.04+ 5.46 2.70-11.04 
<.0001 
Hypothesis 2a:  Is there an association between the initial troponin level and heart failure readmission among 
patients who were alive 365 post discharge 
Unadjusted model 
Initial Troponin 
<0.04 
0.04+ 1.27 0.37-4.34 
.708 
Adjusted for age, race, sex 
Initial Troponin 
<0.04 
0.04+ 1.03 0.29-3.65 
.967 
Adjusted for age, race, sex, smoking and eGFR 
Initial Troponin 
<0.04 
0.04+ 1.10 0.29-4.13 
.893 
Hypothesis 3:  Is there an association between the initial troponin level and selected chronic medical 
conditions among patients without ACS and who were alive 365 post discharge 
Unadjusted model 
Heart Failure - 
Initial Troponin 
<0.04 
0.04+ 3.63 2.82-4.66 
<.0001 
Diabetes – 
Initial Troponin 
<0.04 
0.04+ 1.44 1.13-1.82 
.003 
Hypertension - 
Initial Troponin 
<0.04 
0.04+ 2.31 1.56-3.44 
<.0001 
Left ventricular hypertrophy - 
Initial Troponin 
<0.04 
0.04+ 2.39 1.65-3.46 
<.0001 
Chronic kidney disease - 
Initial Troponin 
<0.04 
0.04+ 2.68 2.07-3.47 <.0001 
Any of the above chronic medical 
conditions - 
Initial Troponin 
<0.04 
0.04+ 3.84 2.26-6.52 
<.0001 
Adjusted for age, race, sex 
Table 12 continued
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Outcome OR 95% CI p-value*
Heart Failure - 
Initial Troponin 
<0.04 
0.04+ 2.40 1.81-3.17 
<.0001 
Diabetes – 
Initial Troponin 
<0.04 
0.04+ 1.03 0.79-1.34 
.846 
Hypertension - 
Initial Troponin 
<0.04 
0.04+ 1.22 0.46-1.97 
.407 
Left ventricular hypertrophy - 
Initial Troponin 
<0.04 
0.04+ 1.86 1.25-2.79 
.002 
Chronic kidney disease - 
Initial Troponin 
<0.04 
0.04+ 2.06 1.54-2.75 
<.0001 
Any of the above chronic medical 
conditions - 
Initial Troponin 
<0.04 
0.04+ 1.68 0.92-3.06 
.092 
Adjusted for age, race, sex, smoking and eGFR 
Heart Failure - 
Initial Troponin 
<0.04 
0.04+ 2.15 1.35-3.42 
.001 
Diabetes – 
Initial Troponin 
<0.04 
0.04+ 0.73 0.47-1.14 
.167 
Hypertension - 
Initial Troponin 
<0.04 
0.04+ 1.46 0.46-4.57 
.520 
Left ventricular hypertrophy - 
Initial Troponin 
<0.04 
0.04+ 2.11 1.18-3.77 
.012 
Chronic kidney disease - 
Initial Troponin 
<0.04 
0.04+ 0.88 0.470-1.64 
.688 
Any of the above chronic medical 
conditions - 
Initial Troponin 
<0.04 
0.04+ 4.08 0.51-32.32 
.183 
Table 12 continued
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5.3 HYPOTHESIS 3 
The third hypothesis of this dissertation examines whether there is an association between initial 
cTnI level and selected medical conditions among patients without ACS who were alive 365 post 
discharge.  Specific medical conditions of interest included HF, diabetes, hypertension, LVH, 
CKD and any of these medical conditions.  Patients with initial cTnI levels >0.04 ng/mL 
compared to patients with lower initial cTnI levels were more likely to have HF (49.1% versus 
21.09%) diabetes (51.7% versus 42.7%), hypertension (91.5% versus 82.3%), LVH (14.9% 
versus 6.8%), and CKD (38.7% versus 19.1%), all p<0.0001, (Table 11).  The prevalence of any 
of these chronic medical conditions was extremely high in this population but nevertheless, 
95.8% of patients with higher initial cTnI levels, compared to 85.4% of patients with  lower 
levels ( p<0.0001) had at least one of these important medical conditions. 
In the unadjusted logistic model, the odds of having these selected medical conditions 
was significantly higher among patients with initial troponin levels >0.04ng/mL.: HF, (OR=3.63; 
2.82, 466); diabetes, (OR=1.44; 1.13, 1.82); hypertension, (OR=2.3; 1.56, 3.44); LVH, 
(OR=2.39; 1.65, 3.46); CKD, OR=2.68; 2.07, 3.47); and any of the above medical conditions, 
(OR=3.84; 2.26, 6.52), Table 12.  However, after adjusting for age, race and sex, only the 
associations with HF, LVH and CKD remained statistically significant.  In models further 
adjusted for smoking and eGFR, only the association with HF, (OR=2.15; 1.35, 3.42) and LVH 
(OR=2.11; 1.18, 3.77) remained significant.   
We additionally categorized troponin by the manufacturer’s biometric assay reference 
range:   range 0.04-0.099ng/mL (negative); 0.10-0.60ng/mL (indeterminate) and >0.60ngml 
(positive), (Table 13). In general, patients with elevated serum troponin >0.04ng/mL had an 
increased risk of heart failure and LVH.  However, there was no clear trend likely reflecting the 
smaller sample sizes in some of these strata.  The magnitude of odds ratio ranged from 1.58 
(diabetes) to 4.04 (any of the medical conditions), (Table 13).  Adjusting models for age, race 
and sex attenuated associations with diabetes, hypertension, and any condition.  Further adjusting 
for smoking and eGFR, patients with elevated serum cTnI were more than 2-fold more likely to 
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have HF and LVH but there was no association between troponin and diabetes, hypertension, 
CKD or any of these conditions, (Table 13). 
Table 13. Is there an Association Between the Initial Troponin Level and Selected Chronic Medical 
Conditions Among Patients Without ACS who were Alive 365 Post Discharge: Stratification of 
Serum Troponin Levels 
Outcome OR 95% CI p-value*
Unadjusted model 
Heart Failure - 
Initial Troponin 
<0.04 
0.04-.099 
.10-.599 
.60+ 
1.00 
3.24 
6.15 
2.05 
2.46-4.28 
3.81-9.92 
0.75-5.61 
<0.0001 
Diabetes – 
Initial Troponin 
<0.04 
0.04-.099 
.10-.599 
.60+ 
1.00 
1.35 
1.87 
1.19 
1.04-1.76 
1.18-2.97 
0.46-3.11 
0.013 
Hypertension - 
Initial Troponin 
<0.04 
0.04-.099 
.10-.599 
.60+ 
1.00 
2.11 
2.61 
-- 
1.36-3.25 
1.12-6.09 
-- 
0.0005 
Left ventricular hypertrophy - 
Initial Troponin 
<0.04 
0.04-.099 
.10-.599 
.60+ 
1.00 
2.47 
2.70 
-- 
1.65-3.70 
1.42-5.12 
-- 
<.0001 
Chronic kidney disease - 
Initial Troponin 
<0.04 
0.04-.099 
.10-.599 
.60+ 
1.00 
2.41 
4.13 
1.77 
1.81-3.22 
2.59-6.59 
0.62-5.07 
<.0001 
Any of the above chronic medical 
conditions - 
Initial Troponin 
<0.04 
0.04-.099 
.10-.599 
.60+ 
1.00 
3.82 
3.19 
-- 
2.09-6.98 
1.15-8.86 
-- 
<.0001 
Adjusted for age, race, sex 
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Outcome OR 95% CI p-value*
Unadjusted model 
Heart Failure - 
Initial Troponin 
<0.04 
0.04-.099 
.10-.599 
.60+ 
1.00 
2.04 
4.52 
1.65 
1.49-2.79 
2.67-7.66 
0.54-5.05 
<.0001 
Diabetes – 
Initial Troponin 
<0.04 
0.04-.099 
.10-.599 
.60+ 
1.00 
0.95 
1.29 
1.20 
0.71-1.28 
0.78-2.11 
0.41-3.55 
.727 
Hypertension - 
Initial Troponin 
<0.04 
0.04-.099 
.10-.599 
.60+ 
1.00 
1.12 
1.39 
-- 
0.66-1.89 
0.53-3.62 
-- 
.754 
Left ventricular hypertrophy - 
Initial Troponin 
<0.04 
0.04-.099 
.10-.599 
.60+ 
1.00 
1.93 
2.06 
-- 
1.25-2.98 
1.04-4.06 
-- 
.005 
Chronic kidney disease - 
Initial Troponin 
<0.04 
0.04-.099 
.10-.599 
.60+ 
1.00 
1.81 
3.30 
1.62 
1.32-2.50 
1.98-5.52 
0.51-5.12 
<.0001 
Any of the above chronic medical 
conditions - 
Initial Troponin 
<0.04 
0.04-.099 
.10-.599 
.60+ 
1.00 
1.75 
1.28 
-- 
0.87-3.51 
0.44-3.69 
-- 
.274 
Adjusted for age, race, sex, smoking and eGFR 
Heart Failure - 
Initial Troponin 
<0.04 
0.04-.099 
.10-.599 
.60+ 
1.00 
1.73 
4.88 
2.48 
1.04-2.90 
1.92-12.44 
0.47-13.20 
.003 
Diabetes – 
Initial Troponin 
<0.04 
0.04-.099 
.10-.599 
.60+ 
1.00 
0.72 
0.66 
1.42 
0.44-1.17 
0.29-1.52 
0.25-7.99 
.463 
Table 13 continued
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Outcome OR 95% CI p-value*
Unadjusted model 
Hypertension - 
Initial Troponin 
<0.04 
0.04-.099 
.10-.599 
.60+ 
1.00 
1.20 
1.78 
-- 
0.33-4.43 
0.21-14.82 
-- 
.844 
Left ventricular hypertrophy - 
Initial Troponin 
<0.04 
0.04-.099 
.10-.599 
.60+ 
1.00 
2.26 
2.19 
-- 
1.21-4.22 
0.82-5.83 
-- 
.025 
Chronic kidney disease - 
Initial Troponin 
<0.04 
0.04-.099 
.10-.599 
.60+ 
1.00 
0.75 
1.66 
0.68 
0.38-1.49 
0.53-5.18 
0.06-7.87 
.606 
Any of the above chronic medical 
conditions - 
Initial Troponin 
<0.04 
0.04-.099 
.10-.599 
.60+ 
1.00 
-- 
1.23 
-- 
-- 
0.14-10.59 
-- 
.852 
Table 13 continued
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6.0  DISCUSSION 
The Pittsburgh Veteran’s Healthcare System implemented a process to obtain cTnI levels on all 
patients with any complaint of discomfort between their ears and their hips.  The purpose of this 
policy was to improve early identification of patients with ACS.  The purpose of this dissertation 
was to evaluate this policy and test whether patients with elevated cTnI levels (>0.04ng/mL) 
have an increased risk of death one year after discharge.  Since troponin levels are an established 
biomarker for AMI, we excluded patients with AMI and patients who died in the hospital. 
Results showed that patients with elevated serum troponin levels were 2.3 times more likely to 
die within one year after they were discharged.  We also showed that this association was 
slightly stronger in patients with ACS (almost 3.8-fold increased risk of dying).  However, even 
among patients without ACS, there was a 2.0-fold increased risk of mortality among those with 
elevated troponin levels.  The interaction between ACS and troponin level was, however, not 
significant. 
Patients with serum cTnI levels at initial hospitalization >0.04ng/mL were also more 
likely to have an AMI within a year of their initial admission.  This association was independent 
of age, race, sex, smoking and renal function.  Patients with elevated cTnI levels also had a >5-
fold increased risk of MI.  There was, however, no association between cTnI and HF 
readmissions.  However, in the subset of patients without ACS, initial troponin level was 
associated with a 2-fold increased risk of developing HF and LVH but there was no association 
between cTnI and diabetes, hypertension, CKD or any of these medical conditions.  These results 
support the use of a broad based recommendation to continue measuring cTnI levels on patients 
with pain from their ears to their hip at the VA Pittsburgh Healthcare System. 
Our results between elevated serum cTnI and increased mortality and MI risk are 
consistent with previous studies [45].  In addition, the predictive value of cTnI extend beyond 
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MI.  We showed that those with elevated troponin were more likely to be hospitalized for heart 
failure and left ventricular hypertrophy.  This finding is also consistent with previous research 
[48]. 
Elevated serum troponin I levels have been shown to provide prognostic information for 
hypertension [49] and diabetes [150].  However, we found no association between troponin and 
diabetes or hypertension.  
Patients with elevated serum troponin levels were more likely to have CKD in the 
unadjusted and age, sex, race adjusted models.  The association was quite strong showing a 2-
fold increased risk. However, this association was attenuated in models adjusting for eGFR.  
This latter adjustment is likely over adjustment since individual with lower GFR are more likely 
to have chronic kidney disease.  Chronic kidney disease may reflect a mechanism whereby 
elevated serum troponin predicts heart failure and left ventricular hypertrophy. 
In the fully adjusted model, we found no significant association between serum troponin 
and any of the chronic diseases combined as an aggregate. This may reflect the very high 
prevalence of any of these diseases in patients both with and without elevated serum troponin.  
The level of comorbidity was high in these older veterans. 
6.1 STRENGTHS AND WEAKNESSES 
We carried out a large retrospective study and comprehensively evaluated all patients with a 
serum troponin I level drawn in fiscal year 2010.  We worked with the Veteran’s Affairs Medical 
Data System and programmers at the Veteran’s Affairs Healthcare System in Pittsburgh familiar 
with the data system.  Thus, our ascertainment of patients who met our entry criteria was likely 
very high.  We were able to adjust for important demographic and lifestyle factors (e.g, 
smoking).   
There are, however, several weaknesses.  We did not have information on medication use 
which could have influenced subsequent outcomes.  The diagnostic sensitivity of troponin varies 
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by when the troponin is measured after admission.  Peak values occur 8 to 16 hours after the 
onset of symptoms [1].  We had no information on the timing of the troponin blood draw and the 
onset of symptoms.  Finally, our subjects were all US veterans with a high level of comorbidity 
and, therefore, our results may not be generalizable to patients admitted to general community 
hospitals.   
6.2 PUBLIC HEALTH REVELANCE 
CVD is the leading cause of death in both men and women, killing over 600,000 people 
annually.  Diseases of the heart accounted for about 25% of deaths [154].  Troponin levels have 
been identified as a key biomarker of heart disease.  Raised troponin levels indicate cardiac 
muscle cell death as the enzyme is released into the blood upon injury to the heart.  The VA 
Health System in Pittsburgh instituted a policy to measure troponin I levels on all patients with 
pain between their ears and hips.  It is critical to evaluate whether this policy is effective in 
identifying patients at risk of death, MI and other diseases.  The VA Health System is 
constrained by current healthcare funding.  It is important to evaluate whether the cost of these 
assays are justified.  Indeed, in 2010, over 2000 patients had a troponin level drawn.  Our study 
showed that this practice will identify patients at risk of dying, developing MI, heart failure or 
left ventricular hypertrophy.  These results are important from a public health perspective, given 
that CVD is the leading cause of death in the United States.  
6.3 CONCLUSION 
Elevated serum troponin levels (>0.04ng/mL) are predictive of overall mortality, MI, HF and 
LVH.  Our results suggest that the VA Health System should continue to measure troponin on 
patients with pain between their hips and ears.  Patients admitted with elevated troponin levels 
should be targeted for interventions to prevent death, MI, HF and LVH.   
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